TCT-720 Patient-Reported Outcomes in Tricuspid Valve Intervention: Patient Preference Results From the TRISCEND II Trial
Recommended Citation
Brener M, Barker C, Davidson C, Narang A, Sharma R, Haeffele C, Yadav P, Thourani V, Kodali S, Hahn R, Makkar R, Makar M, Hausleiter J, Nabauer M, O'Neill W, Wang D, Lindman B, Zahr F, Chadderdon S, Eleid M, Pislaru S, Mancilla M, Kemp L, Mollenkopf S, Ryan M, Cohen D. TCT-720 Patient-Reported Outcomes in Tricuspid Valve Intervention: Patient Preference Results From the TRISCEND II Trial. 2023; :B289-B290.
Document Type
Conference Proceeding
Publication Date
10-24-2023
Abstract
Background: Validated patient reported outcome measures for tricuspid regurgitation (TR) are lacking. To address this knowledge gap, we assessed patient priorities for improvement during evaluation for treatment of TR. Methods: Participants in the prospective, multicenter TRISCEND II pivotal randomized trial, comparing outcomes of the EVOQUE transcatheter tricuspid valve replacement (TTVR) system (Edwards Lifesciences) plus optimal medical therapy (OMT) vs OMT alone for at least severe TR were administered a patient preference survey at baseline. Survey questions assessed patients’ priorities for improvement in 6 symptoms (swelling in legs, ankles, and feet; fatigue; poor sleep; depression or anxiety; shortness of breath) and 6 activities (self-care; walking 1 block on level ground; climbing stairs; performing work, chores, or hobbies; recreational activities; and visiting family and friends). Results: 131 trial participants completed the survey correctly. For symptoms, participants most frequently prioritized improvement in shortness of breath (37.4%) and fatigue (23.7%) (see Table 1). For activities, patients prioritized self-care (54.2%) and ability to visit family/friends outside of the home (10.7%). Ongoing analyses will examine the relationship between patient preferences, changes in health status, and treatment assignment. [Formula presented] Conclusion: Among patients undergoing treatment for severe TR in the TRISCEND II RCT, improvements in dyspnea and independence were identified as key goals of therapy. The relationship between these goals and health status outcomes with TTVR vs medical therapy will be presented and will provide novel insights into the value of TTVR from the patient’s perspective. Categories: STRUCTURAL: Valvular Disease: Tricuspid
First Page
B289-B290
